CGRP mAb Subcutaneous denied as not FDA-approved for this use by UnitedHealthcare?

UnitedHealthcare's specific coverage criteria for cgrp mab subcutaneous are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why UnitedHealthcare Denies CGRP Monoclonal Antibodies as Not FDA-Approved

This denial is most commonly issued when the prescribed subcutaneous CGRP monoclonal antibody is being used for an indication — or in a patient population — that differs from the exact labeling approved by the FDA. UnitedHealthcare's coverage policies generally tie coverage to FDA-approved indications, and when the clinical documentation suggests use outside those bounds (for example, a diagnosis code that does not match the approved indication), reviewers issue a not-FDA-approved denial. In rarer cases the denial reflects an administrative coding mismatch rather than a genuine off-label situation.

## Why This Denial Is Appealable

This type of denial is an adverse benefit determination subject to the same internal and external appeal rights as any other denial. Under ACA §2719, you have access to independent external review after exhausting internal appeals. ERISA §503 governs employer-sponsored plans. The external-review window is typically 4 months from a final internal denial, with an expedited pathway available for urgent cases.

Moreover, many states and federal guidance documents recognize that off-label use of FDA-approved drugs can be medically necessary and covered when supported by authoritative clinical compendia or peer-reviewed literature. If the use is truly off-label, that is a separate legal argument from a use that falls squarely within the approved indication but was miscoded.

## The Appeal Process

1. Confirm the exact FDA-approved indication(s) by reviewing the current prescribing information for the specific CGRP monoclonal antibody prescribed. 2. Determine whether the patient's documented diagnosis falls within an approved indication — if it does, the denial may rest on a coding error, and a corrected claim or peer-to-peer call may resolve it quickly. 3. If the use is off-label, file a written appeal citing applicable clinical compendia (e.g., DRUGDEX, AHFS) and peer-reviewed published literature supporting the use. 4. Escalate to external review if the internal appeal is denied.

## Documentation to Gather

• Confirmed diagnosis records: Specialist notes that clearly establish the diagnosis and tie it to the FDA-approved indication.
• Prescribing-label excerpt: A copy of the relevant indication section of the FDA label showing coverage of this patient's condition.
• Off-label support (if applicable): Published clinical literature or compendia citations reviewed and summarized by the prescriber.
• Prescriber letter: A letter explicitly mapping the patient's documented condition to the approved (or supported off-label) indication.

## Criteria-Mapping Structure

Obtain UHC's Coverage Determination Guideline for this drug and the FDA-approved labeling. For each coverage criterion, provide the matching chart citation. Where the denial appears to be a coding mismatch, document the corrected diagnosis and explain the discrepancy plainly.